• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    EDP Renewables Starts Construction on 240-Megawatt Texas Solar Park

    9/20/22 10:00:00 AM ET
    $BMY
    $FB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Internet and Information Services
    Technology
    Get the next $BMY alert in real time by email

    Houston, Texas, Sept. 20, 2022 (GLOBE NEWSWIRE) -- EDP Renewables North America (EDPR NA), a leading renewable energy developer and operator in North America, announces the start of construction on its 240-megawatt (MW) Cattlemen I Solar Park in Milam County, Texas.

    Cattlemen Solar Park, which was developed and constructed and will be operated by EDPR NA, will bring a wealth of economic benefits to Milam County and the greater central Texas region through millions of dollars that will be paid to local landowners, a projected $55 million in taxes that will be paid to support area schools and community services, and millions of dollars that will be spent locally during the project's construction and multi-decade operational life. Cattlemen will also support local jobs – both in the 400 employment opportunities created during construction and the several full-time team members who will be employed to safely run and perform routine maintenance on the park during operations. Once online in 2023, Cattlemen's generation will be equivalent to the consumption of more than 37,000 average Texas homes. Cattlemen will also save more than 304 million gallons of water and avoid more than 271,000 tons of CO2 each year that would be needed by conventional generation sources to produce the same amount of energy capacity as the solar park.

    "Cattlemen is EDP Renewables' first solar park in Texas and will soon be our largest operational solar park in our North American portfolio," Kris Cheney, EDP Renewables North America Executive Vice President – Central and Western Regions and Mexico, Environmental Affairs, and Energy Storage Analytics said. "The Milam County community has been a great partner throughout Cattlemen's development. As we move closer to operation, we look forward to continuing that partnership as a contributing member of the community and expanding upon our relationship with the landowners, local officials, and residents."

    EDP Renewables is a clean energy leader in Texas. The company's North American headquarters is in Houston and it operates six wind energy projects throughout the state, including two phases of the Lone Star Wind Farm, two phases of the Los Mirasoles Wind Farm, the Reloj del Sol Wind Farm, and the Wildcat Creek Wind Farm. The projects' total operating capacity is 1,089 MW, which generate enough electricity to annually power more than 236,000 average homes in Texas. EDPR's Texas presence totals an estimated $1.9 billion in capital investment and more than 550 jobs.

    Cattlemen has two long-term commercial agreements in-place for the project: a 156-MW power purchase agreement (PPA) with Meta (NYSE:FB) and a 60-MW PPA with Bristol Myers Squibb (NYSE:BMY). Cattlemen Solar Park is the second PPA that EDP Renewables and Meta have executed; the companies' first PPA was a 139-MW contract for EDPR NA's 200-MW Headwaters II Wind Farm in Indiana.

    Multimedia resources include:

    • EDPR NA: Fact Sheet
    • Cattlemen Solar Park: Fact Sheet
    • EDPR NA Texas: Fact Sheet
    • Economic benefits of solar: Fact Sheet
    • Solar Power in North America: Video

    ###

    About EDP Renewables North America

    EDP Renewables North America LLC (EDPR NA), its affiliates, and its subsidiaries develop, construct, own, and operate wind farms and solar parks throughout North America. Headquartered in Houston, Texas, with 58 wind farms, nine solar parks, and eight regional offices across North America, EDPR NA has developed more than 8,800 megawatts (MW) and operates more than 8,200 MW of onshore utility-scale renewable energy projects. With more than 950 employees, EDPR NA's highly qualified team has a proven capacity to execute projects across the continent.

    For more information, visit www.edpr.com/north-america.

    About EDP Renewables

    EDPR NA is a wholly owned subsidiary of EDP Renewables (Euronext: EDPR), a global leader in

    the renewable energy sector. EDPR is the fourth largest renewable energy producer worldwide with a presence in 28 markets across Europe, North America, South America and Asia Pacific. Based in Madrid and with main regional offices in Houston, São Paulo and Singapore, EDPR has a robust development portfolio with first-class assets and a market-leading operational capability in renewables. These include wind onshore, utility scale and distributed solar, wind offshore (through its 50/50 JV - OW) and technologies complementary to renewables such as batteries and green hydrogen. EDPR's employee-centered policies resulted in its recognition as a Top Workplace 2022 in the United States, Top Employer 2022 in Europe (Spain, Italy, France, Romania, Portugal and Poland) and Brazil, as well as its inclusion in the Bloomberg Gender-Equality Index.

    EDPR is a division of EDP (Euronext: EDP), a leader in the energy transition with a focus on decarbonization. Besides its strong presence in renewables (with EDPR and hydro operations), EDP has an integrated utility presence in Portugal, Spain and Brazil including electricity networks, client solutions and energy management. EDP – EDPR's main shareholder – has been listed on the Dow Jones Index for 14 consecutive years, recently being named the most sustainable electricity company on the Index.

    Attachments

    • EDP Renewables Logo
    • Cattlemen Solar Park Logo


    Blair Matocha
    EDP Renewables North America
    713-356-2415
    [email protected]
    
    Get the next $BMY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BMY
    $FB

    CompanyDatePrice TargetRatingAnalyst
    Bristol-Myers Squibb Company
    $BMY
    8/5/2025$42.00Outperform → Neutral
    Daiwa Securities
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025$55.00Neutral
    Cantor Fitzgerald
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025Overweight
    Piper Sandler
    Bristol-Myers Squibb Company
    $BMY
    12/16/2024$70.00Hold → Buy
    Jefferies
    Bristol-Myers Squibb Company
    $BMY
    12/10/2024$63.00Neutral
    BofA Securities
    Bristol-Myers Squibb Company
    $BMY
    11/15/2024Peer Perform
    Wolfe Research
    Bristol-Myers Squibb Company
    $BMY
    11/13/2024Neutral → Outperform
    Daiwa Securities
    Bristol-Myers Squibb Company
    $BMY
    11/12/2024$73.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $BMY
    $FB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

    First Breakthrough Therapy Designation in the U.S. for SystImmune and Bristol Myers Squibb's Izalontamab brengitecan (Iza-bren) based on data from the BL-B01D1-101 (CN), BL-B01D1-203 (CN), and BL-B01D1-LUNG-101 (U.S.,/EU) studiesREDMOND, Wash. and PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to izalontamab brengitecan (iza-bren) for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor (EGFR) exon 19 deletions or e

    8/18/25 6:00:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)

    Breyanzi has the potential to be the first and only CAR T cell therapy approved for MZL, addressing a high unmet need Application based on results from MZL cohort of TRANSCEND FL presented at ICML in which Breyanzi demonstrated high rates of durable responses and a consistent safety profile Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) for Breyanzi® (lisocabtagene maraleucel; liso-cel) as a potential treatment for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy. The FDA has granted the

    8/4/25 4:16:00 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas

    NetworkNewsWire Editorial Coverage NEW YORK, Aug. 4, 2025 /PRNewswire/ -- As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trump administration's "Make America Healthy Again" initiatives have emphasized improving access to treatments and accelerating me

    8/4/25 8:30:00 AM ET
    $BMY
    $INSM
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $FB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    4/29/25 6:14:13 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Boerner Christopher S. bought $110,096 worth of shares (2,000 units at $55.05), increasing direct ownership by 2% to 104,626 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    2/21/25 7:09:34 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $100,000 worth of shares (1,823 units at $54.84), increasing direct ownership by 3% to 63,932 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    2/19/25 7:19:54 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $FB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by EVP,Chief Med Offr,Head of Dev Massacesi Cristian

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    8/5/25 6:16:48 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Massacesi Cristian

    3 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    8/5/25 6:15:11 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, General Counsel Gallman Cari converted options into 1,061 shares and covered exercise/tax liability with 543 shares, increasing direct ownership by 6% to 8,840 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    8/5/25 6:01:33 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $FB
    SEC Filings

    View All

    SEC Form 10-Q filed by Bristol-Myers Squibb Company

    10-Q - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

    7/31/25 12:17:29 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol-Myers Squibb Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

    7/31/25 7:06:45 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol-Myers Squibb Company filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

    7/25/25 4:43:19 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $FB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $BMY
    $FB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

    For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

    9/26/24 6:42:20 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 14, 2024 - FDA Roundup: June 14, 2024

    For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

    6/14/24 3:54:45 PM ET
    $MMSI
    $BMY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    March 8, 2024 - FDA Roundup: March 8, 2024

    For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

    3/8/24 3:26:46 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol-Myers downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Bristol-Myers from Outperform to Neutral and set a new price target of $42.00

    8/5/25 7:09:09 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Bristol-Myers with a new price target

    Cantor Fitzgerald initiated coverage of Bristol-Myers with a rating of Neutral and set a new price target of $55.00

    4/22/25 8:00:39 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Bristol-Myers

    Piper Sandler initiated coverage of Bristol-Myers with a rating of Overweight

    4/22/25 7:30:03 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $FB
    Leadership Updates

    Live Leadership Updates

    View All

    Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

    Dr. Massacesi will join BMS August 1 and serve on the Executive Leadership Team Samit Hirawat, M.D., Executive Vice President, to step down from his role on August 1 and will depart BMS on November 1 Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. In this role, Dr. Massacesi will oversee the company's early-stage and late-stage product development across all therapeutic areas. "We are thrilled to welcome Cristian to Bristol Myers Squibb," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. "His d

    7/25/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

    Gallman's Appointment is Effective Immediately Sandra Leung, Executive Vice President, General Counsel Retires After 33 Years of Service Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (Sandy) Leung, who has chosen to retire after an extraordinary 33-year career at the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506937441/en/Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Gallman, an accomplished leade

    5/6/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer

    Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted

    3/20/25 8:00:00 AM ET
    $APLS
    $BIIB
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $BMY
    $FB
    Financials

    Live finance-specific insights

    View All

    Bristol Myers Squibb Reports Second Quarter Financial Results for 2025

    Bristol Myers Squibb (NYSE:BMY) today reported second quarter 2025 financial results. Visit the company's Investor Relations website at http://investor.bms.com to view the detailed second quarter 2025 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, July 31, 2025, which is accessible here. Company executives will review financial results with the investment community during the call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb: Transforming Patients' Lives T

    7/31/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol Myers Squibb Announces Dividend

    Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on August 1, 2025, to stockholders of record at the close of business on July 3, 2025. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on September 2, 2025, to stockholders of record at the close of business on August 5, 2025. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, de

    6/17/25 4:16:00 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025

    Bristol Myers Squibb (NYSE:BMY) will announce results for the second quarter of 2025 on Thursday, July 31, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol

    6/12/25 6:45:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $FB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Bristol-Myers Squibb Company (Amendment)

    SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)

    2/9/23 11:12:40 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Meta Platforms Inc. (Amendment)

    SC 13G/A - Meta Platforms, Inc. (0001326801) (Subject)

    2/14/22 4:03:05 PM ET
    $FB
    Internet and Information Services
    Technology

    SEC Form SC 13G/A filed by Meta Platforms Inc. (Amendment)

    SC 13G/A - Meta Platforms, Inc. (0001326801) (Subject)

    2/10/22 8:11:43 AM ET
    $FB
    Internet and Information Services
    Technology